Dr. Morgan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Summary
- I am a board certified urologic surgeon specializing in the treatment of genitourinary malignancies. Previously at Vanderbilt University, I joined the faculty at the University of Michigan in 2012. I am originally from Seattle, WA, and completed my undergraduate and medical training at Harvard University. I returned to the Northwest in 2003 for his urology residency at the University of Washington, before moving to Nashville for my fellowship training in urological oncology and subsequent faculty appointment at Vanderbilt. My research focuses on understanding the early spread of prostate cancer cells, with the aim of identifying those patients with the most aggressive tumors and developing appropriate therapeutic strategies for these individuals.
Education & Training
- Vanderbilt University Medical CenterFellowship, Minimally Invasive Urologic Surgery, 2009 - 2011
- University of WashingtonResidency, Urology, 2003 - 2009
- University of WashingtonResidency, Surgery, 2003 - 2005
- Harvard Medical SchoolClass of 2003
- Harvard UniversityAB, 1995 - 1999
Certifications & Licensure
- MI State Medical License 2012 - 2025
- TN State Medical License 2009 - 2013
- WA State Medical License 2003 - 2009
- American Board of Urology Urology
Awards, Honors, & Recognition
- Outstanding Reviewer in Prostate Cancer Journal of Urology, 2012
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Best Poster American Urological Association, 2011
- Join now to see all
Clinical Trials
- Genomics in Michigan Impacting Observation or Radiation Start of enrollment: 2017 Jan 17
- Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer Start of enrollment: 2017 Sep 14
- Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer Start of enrollment: 2020 Nov 05
Publications & Presentations
PubMed
- Spatial Transcriptomic Profiling to Characterize the Nature of Peripheral- Versus Transition-zone Prostate Cancer.Parth Patel, Srinivas Nallandhighal, David Scoville, Brittney Cotta, Zayne Knuth
European Urology Focus. 2024-11-28 - 1 citationsIntegrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.Nathan M Merrill, Samuel D Kaffenberger, Liwei Bao, Nathalie Vandecan, Laura Goo
European Urology. 2024-11-01 - Financial Implications of Prostate Magnetic Resonance Imaging Without Contrast.Benjamin Pockros, Matthew Davenport, Mitchell Mead, Ruchika Talwar, Samuel Kaffenberger
Urology Practice. 2024-11-01
Journal Articles
- Editorial Comment: Initial Extended Transrectal Prostate Biopsy-Are More Prostate Cancers Detected With 18 Cores Than With 12 Cores?Morgan, T.M. and Corman, J.M., J Urol, 1/1/2008
- Osteotomy for malunited fractures of the distal radius: a comparison of structural and nonstructural autogenous bone graftsRing D, Roberge C, Morgan T, Jupiter JB, J Hand Surg, 1/1/2002
Press Mentions
- Artera Launches AI Test for Decision-Making on Prostate Cancer Treatment CourseAugust 6th, 2024
- Should We Use PSA to Find Active Surveillance Candidates?April 3rd, 2022
- Video May Aid in Precision Medicine for Prostate CancerOctober 13th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: